The 5th Circuit blocked mifepristone mailing before the FDA finished its own safety review
A federal appeals court has restricted access to one of the most common methods of abortion in the United States, blocking the mailing of mifepristone prescriptions in a ruling that sets up an almost certain Supreme Court showdown. But the most striking detail in the May 1st decision is not the outcome — it is the timing. The 5th Circuit ruled before the FDAs own ongoing safety review of the drug had concluded, with the agency unable to tell the court when its work might be done.NPR
The unanimous three-judge panel of the New Orleans-based 5th U.S. Circuit Court of Appeals ruled that mifepristone must once again be dispensed only in person at clinics, overturning a 2023 FDA rule that had allowed the drug to be prescribed via telemedicine and delivered by mail.STAT News The ruling applies nationwide, including in states where abortion remains legal.
Mifepristone, approved by the FDA in 2000 and used in combination with a second drug called misoprostol, accounts for roughly two out of every three abortions performed in the United States today, according to the Guttmacher Institute. Roughly one in four abortions are now prescribed via telehealth — a pathway the ruling closes.ACLU
The case, brought by the state of Louisiana, argued that allowing mifepristone to be mailed undermined the states ban on abortion at all stages of pregnancy. Every abortion facilitated by FDAs action cancels Louisianas ban on medical abortions and undermines its policy that every unborn child is human being from the moment of conception, the ruling stated.NPR
The ruling is the most significant restriction on abortion access since the Supreme Courts 2022 decision overturning Roe v. Wade, and it comes from the same circuit court that has repeatedly shaped abortion policy in the post-Dobbs era.NPR
What makes this ruling unusual — and consequential for the pharmaceutical industry — is its relationship to an ongoing FDA review. Trump administration officials at the FDA have said the agency is conducting a new safety review of mifepristone at the direction of the president. But as the 5th Circuit noted in its opinion, the FDA could not say when that review might be complete and admitted it was still collecting data. The court did not wait for that process to conclude.NPR
Judges have historically deferred to the FDAs scientific judgment on drug safety and appropriate regulation. That deference is the foundation of a regulatory system designed to insulate scientific agency decisions from political and judicial interference. The 5th Circuit ruling represents a departure from that norm — a federal court restricting distribution of an FDA-approved drug before the agencys own investigation had finished.
The practical consequences extend beyond abortion. Mifepristone is also used in miscarriage care. Medical authorities, including the American College of Obstetricians and Gynecologists, have stated that the in-person dispensing requirement has no safety benefit.ACLU The Guttmacher Institutes Vice President for Public Policy, Kelly Baden, called the decision the most sweeping threat to abortion since the overturning of Roe v. Wade.Guttmacher Institute
Danco, the manufacturer of mifepristone, is seeking Supreme Court review.STAT News Whether the Courts conservative majority — which overturned abortion rights in 2022 but sidestepped the mifepristone question in 2024 on standing grounds — takes up the case remains to be seen. If they do, this time they will have to rule on the merits.NPR
The underlying legal template is what should worry the pharmaceutical industry beyond this specific case. The reasoning Louisiana used to invalidate federal drug distribution rules — that a states abortion ban gives it standing to challenge FDA decisions — is a mechanism that could theoretically be applied to other medications, turning politically contested drugs into test cases for the limits of federal regulatory authority.ACLU